Glaukos Corporation (GKOS): Price and Financial Metrics
GET POWR RATINGS... FREE!
GKOS POWR Grades
- Growth is the dimension where GKOS ranks best; there it ranks ahead of 92.02% of US stocks.
- GKOS's strongest trending metric is Growth; it's been moving up over the last 31 weeks.
- GKOS's current lowest rank is in the Stability metric (where it is better than 34.47% of US stocks).
GKOS Stock Summary
- With a price/sales ratio of 9.58, GLAUKOS Corp has a higher such ratio than 80.84% of stocks in our set.
- With a year-over-year growth in debt of 394.42%, GLAUKOS Corp's debt growth rate surpasses 96.8% of about US stocks.
- GLAUKOS Corp's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -12.24%, greater than the shareholder yield of just 18.56% of stocks in our set.
- Stocks that are quantitatively similar to GKOS, based on their financial statements, market capitalization, and price volatility, are CERS, MRAM, NSTG, VIVE, and ABEO.
- GKOS's SEC filings can be seen here. And to visit GLAUKOS Corp's official web site, go to www.glaukos.com.
GKOS Valuation Summary
- GKOS's price/sales ratio is 9.7; this is 169.44% higher than that of the median Healthcare stock.
- Over the past 74 months, GKOS's price/sales ratio has gone down 9.5.
- Over the past 74 months, GKOS's price/sales ratio has gone down 9.5.
Below are key valuation metrics over time for GKOS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| GKOS | 2021-05-27 | 14.5 | 5.9 | -41.7 | -47.8 |
| GKOS | 2019-02-04 | 14.3 | 14.7 | -175.5 | -173.1 |
| GKOS | 2018-02-02 | 6.9 | 7.8 | -1072.4 | -2033.1 |
| GKOS | 2017-07-18 | 11.1 | 11.5 | 314.0 | 274.8 |
| GKOS | 2017-03-28 | 15.0 | 14.7 | 380.4 | 331.3 |
| GKOS | 2016-09-06 | 11.4 | 9.8 | -923.3 | -2518.9 |
GKOS Stock Price Chart Interactive Chart >
GKOS Price/Volume Stats
| Current price | $49.36 | 52-week high | $99.00 |
| Prev. close | $49.16 | 52-week low | $40.08 |
| Day low | $48.48 | Volume | 300,885 |
| Day high | $50.16 | Avg. volume | 467,630 |
| 50-day MA | $72.40 | Dividend yield | N/A |
| 200-day MA | $77.13 | Market Cap | 2.28B |
Glaukos Corporation (GKOS) Company Bio
Glaukos Corporation develops and commercializes products and procedures designed for the treatment of glaucoma. The company was founded in 1998 and is based in Laguna Hills, California.
Latest GKOS News From Around the Web
Below are the latest news stories about GLAUKOS Corp that investors may wish to consider to help them evaluate GKOS as an investment opportunity.
Glaukos Corporation (GKOS): Are Hedge Funds Right About This Stock?Is Glaukos Corporation (NYSE:GKOS) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. […] |
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Society of Cataract and Refractive Surgery Annual MeetingSAN CLEMENTE, Calif., July 22, 2021--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held July 23–27, 2021 in Las Vegas, Nevada. |
Why Glaukos Stock Sank TodayWhat happened Shares of Glaukos (NYSE: GKOS) were sinking 14.7% as of 3:28 p.m. EDT on Tuesday. The decline came after Wells Fargo analyst Larry Biegelsen downgraded the stock to an underweight rating from equal weight. |
Glaukos (GKOS) is Oversold: Can It Recover?Glaukos (GKOS) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. |
Glaukos Corporation to Release Second Quarter 2021 Financial Results after Market Close on August 5SAN CLEMENTE, Calif., July 15, 2021--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2021 financial results after the market close on Thursday, August 5, 2021. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on August 5, 2021. |
GKOS Price Returns
| 1-mo | -39.86% |
| 3-mo | -47.58% |
| 6-mo | -44.35% |
| 1-year | 16.69% |
| 3-year | 24.80% |
| 5-year | 41.19% |
| YTD | -34.41% |
| 2020 | 38.17% |
| 2019 | -3.03% |
| 2018 | 118.99% |
| 2017 | -25.22% |
| 2016 | 38.92% |
Continue Researching GKOS
Want to do more research on GLAUKOS Corp's stock and its price? Try the links below:GLAUKOS Corp (GKOS) Stock Price | Nasdaq
GLAUKOS Corp (GKOS) Stock Quote, History and News - Yahoo Finance
GLAUKOS Corp (GKOS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...